B-type natriuretic peptide: Physiologic role and assay characteristics

Heart Failure Reviews

Volumn 8, Issue 4, 2003, Pages 315-320

  Azzazy, Hassan M E ^a   Christenson, Robert H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

B type natriuretic peptide; Immunoassay; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ASSAY; CARDIOVASCULAR FUNCTION; CONGESTIVE HEART FAILURE; ENDOCRINE FUNCTION; HEALTH CARE; HEART LEFT VENTRICLE; HEART VENTRICLE OVERLOAD; HEART VOLUME; HOMEOSTASIS; HUMAN; KIDNEY FUNCTION; PHYSIOLOGY; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; REGULATORY MECHANISM; REVIEW;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; BRAIN; CARDIAC VOLUME; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; IMMUNOASSAY; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN;

EID: 0348155728     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026182912461     Document Type: Review

References (40)

1. Maisel A. B-type natriuretic peptide levels: A potential novel "white count" for congestive heart failure. J Cardiac Failure 2001;7:183-193.
2. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-498.
3. Boomama F, Van Der Meiracker AH. Plasma A- and B-type natriuretic peptides: Physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-449.
4. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr., McCormick MT, Rodriguez-Paz G, Schocken DD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-1140.
5. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752-759.
6. Ambrose TM. Review of the clinical utility of NT-proBNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay 2002;25:160-166.
7. De Bold AJ, Bruneau BG, Kuroski De Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31:7-18.
8. Mair J, Hammerer-Lercher A, Puchendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-588.
9. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
10. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC Jr. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689.
11. Selvais P, Donckier J, Robert A, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest 1998;28:636-642.
12. Yamamota K, Burnett J, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-994.
13. Clerico A, Iervasi G, Del Chicca M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-179.
14. Janssen WM, De Zeeuw D, Van Der Hem GK, De Jong PE. Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension 1989;13:640-646.
15. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412.
16. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-832.
17. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353.
18. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998;95:519-529.
19. Stein B, Levin R. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. American Heart Journal 1998;135:914-923.
20. Weidmann P, Hasler L, Gnadinger MP, Lang RE, Uehlinger DE, Shaw S, Rascher W, Reubi FC. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986;77:734-742.
21. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: Contributions of renal, neurohumoral and hemodynamic factors in sheep. Am J Physiol 1993;264:R533-R538.
22. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic infusions in normal man. J Clin Endocrinol Metab 1996;81:3871-3876.
23. Davidson NC, Struthers AD. Brain natriuretic peptide. Journal of Hypertension 1994;12:329-336.
24. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-498.
25. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. Am Heart J 2002;144:834-839.
26. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
27. Friesinger GC, Francis J. Promises and perils of managed care for older patients with cardiac disease. Cardiol Clin 1999;17:67-77.
28. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, Ford I, McMurray JJ, Dargie HJ. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice. Heart 1997;78:594-597.
29. Buckley MG, Marcus NJ, Yacoub MH, et al. Prolonged stability of brain natriuretic peptide: Importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci 1998;95:235-239.
30. Tsuji T, Imagawa K, Masuda H, Haraikawa M, Shibata K, Kono M, Inouye K, Uchida K. Stabilization of human brain natriuretic peptide in blood samples. Clin Chem 1994;40:672-673.
31. Sagnella GA. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 2001;38:83-93.
32. Kono M, Yamauchi A, Tsuji T, et al. Immunoradiometric assay for brain natriuretic peptide in human plasma. Jpn Soc Nucl Med Technol 1993;13:2-7.
33. BNP Test for Rapid Quantification of B-type Natriuretic Peptide [package insert]. San Diego, Calif: Biosite Diagnostics; 2000.
34. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001;7:21-29.
35. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric assay compared. Clin Chem Lab Med 2001;39:446-450.
36. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) - Validation of an immediate response assay. Clin Lab 2001;47:29-33.
37. Baughman KL. B-type natriuretic peptide - A window to the heart. N Engl J Med 2002;347:158-159.
38. Kelly PM, Gaston S, Mackay R, Arthur K, Taylor V, Shih J, Matias M, Friese J, Weigand R. A novel assay for the measurement of plasma B-type Natriuretic Peptide by an AxSYM® microparticle based immunoassay with use of stable liquid calibrators. Clin Chem 2002;48(suppl):A94, Abst # C-67.
39. Bluestein BI, Belenky A, Lin S, Despres N, Vajdi M, Armstrong G. Development of an automated test for B-type natriuretic peptide (BNP) as an aid in the diagnosis and evaluation of congestive heart failure on the Bayer ADVIA Centaur chemiluminescent system. Clin Chem 2002;48(suppl):A85, Abst # C-37.
40. Sokoll LJ, Baum H, Collinson P, Gurr E, Haass M, Luthe H, Morton I, Nowatzke W, Zingler C. Performance evaluation of Elecsys® proBNP in a multicenter study. Clin Chem 2002;48(suppl):A91, Abst # C-56.